Results 131 to 140 of about 382,253 (265)

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

open access: yesAdvanced Science, EarlyView.
This study shows that a PARP inhibitor combined with anlotinib, administered as bridging therapy, preconditions the tumor microenvironment to enhance the infiltration and antitumor activity of subsequently infused CAR‐T cells across preclinical ovarian cancer models, supporting bridging therapy as a promising strategy to address limited CAR‐T cell ...
Huayi Li   +20 more
wiley   +1 more source

A C‐Nucleoside Analogue of Cordycepin With High Metabolic Stability and Potent Anti‐Psoriatic Activity via Microneedle Delivery

open access: yesAdvanced Science, EarlyView.
This work identified CPD3a as a potent, stable C‐nucleoside cordycepin derivative. When formulated into microneedle array for topical treatment, it ameliorated psoriasis by rebalancing immunity and enhancing antioxidant defenses. ABSTRACT Psoriasis is a chronic inflammatory disorder characterized by immune dysregulation and epidermal hyperplasia ...
Wenfang Pan   +7 more
wiley   +1 more source

Repurposing a Small Molecule Plant Hormone as a Tunable ON‐Switch for CAR‐T Cell Immunotherapy

open access: yesAdvanced Science, EarlyView.
By engineering a receptor system integrating the plant auxin receptor AFB1 with its co‐receptor IAA7, we enable ligand‐dependent interactions triggered by the plant hormone auxins. This design allows rapid, reversible, and dose‐dependent T cell activation, resulting in potent cytotoxicity against B‐cell lymphoma in vitro and in vivo.
Hongxiang Zeng   +16 more
wiley   +1 more source

Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders

open access: yesAdvanced Science, EarlyView.
Antibody can be engineered into diverse lysosome‐targeting chimeras that convert target recognition into active degradation. By coupling antibody binding with recruited receptors, encoded domains, conjugated ligands, or nanoparticle scaffolds, these antibody‐associated targeted chimeras (AbTACs) platforms direct extracellular and membrane proteins ...
Kaige Chen, Quanyin Hu
wiley   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu   +9 more
wiley   +1 more source

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Beyond Simple Mimicry: Next‐Generation Geometric Architectures and Future Paradigms in Small‐Molecule and Macrocyclic Peptidomimetics

open access: yesAngewandte Chemie, EarlyView.
Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee   +5 more
wiley   +2 more sources

Home - About - Disclaimer - Privacy